# A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

> **NCT06213831** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 23 (actual)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** Ruxolitinib Cream 1.5%

## Key facts

- **NCT ID:** NCT06213831
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-27
- **Primary completion:** 2025-07-17
- **Final completion:** 2025-07-17
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06213831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06213831, "A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06213831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*